![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Chiron is arguably the foremost specialist biotechnology R&D company in the world. This profile details the Company's uniquely low ratio of patents per compound derived from the exceptionally large and active development pipeline, the Company's strong associations with large conventional companies such as Ciba-Geigy and their aggressive company acquisition policy which has resulted in rapid sales growth but has adversely affected profitability. The Company's patenting policy and profile is discussed, revealing that 75% of its patenting is classed as pharmaceutical, dominated by virus-orientated projects and with virtually all of its inventors based in the US. This article provides in depth analysis of Chiron's patenting activity and R&D between 1990 and 1995.